Logo of Imugene (ASX:IMU)Latest Imugene (ASX:IMU) News

Page 2
Page 2 of 4

Healthcare Wrap - Week 22 (25 May -> 29 May) 2026

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.
Logan Eniac
30 May 2026

Imugene Expands Azer-cel Trial with BTKi Combo for Resistant Lymphoma Patients

Imugene has dosed the first patient in a new cohort combining its azer-cel CAR T therapy with BTK inhibitors, targeting patients with B-cell malignancies who failed prior BTKi treatment. This move broadens the trial’s scope and tackles a significant unmet need in blood cancer therapy.
Ada Torres
28 May 2026

Market Wrap - Week 21 (18 May -> 22 May) 2026

Battery tech, biotech and balance-sheet repair drove the biggest gains this week, while guidance cuts and weak post-halt trading hurt several names. Deal-making and fresh equity funding stayed busy, especially in rare earths, defence and gold.
Logan Eniac
23 May 2026

Healthcare Wrap - Week 21 (18 May -> 22 May) 2026

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.
Logan Eniac
23 May 2026

Imugene’s Azer-cel Posts 81% Response in CAR T-Naïve Blood Cancer Patients

Imugene Limited’s allogeneic CAR T therapy, azer-cel, delivered an 81% overall response rate in a Phase 1b trial cohort of CAR T-naïve patients with various CD19 B-cell malignancies, with updated data due at ASCO 2026.
Ada Torres
22 May 2026

Market Wrap - Week 12 (16 Mar -> 20 Mar) 2026

A brutal split opened up in small caps: a few stocks surged on hard approvals and funding, while many resource names slid even after announcing big numbers. The week’s tape looked simple: investors paid for certainty and sold anything that still needs time, permits, or more cash.
Logan Eniac
21 Mar 2026

Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.
Logan Eniac
21 Mar 2026

Imugene Unveils $20M Capital Raise to Fuel Azer-cel Clinical Trial Push

Imugene Limited has launched a $20 million equity raising comprising a $12 million placement and an $8 million Share Purchase Plan, alongside issuing options, convertible notes, and warrants to support its azer-cel clinical program.
Ada Torres
17 Mar 2026

Market Wrap - Week 11 (9 Mar -> 13 Mar) 2026

A single biotech result reset expectations in minutes, while gold and critical minerals kept investors busy on deals, drilling and funding. The week’s biggest moves came from one trial being stopped, a miner losing altitude after heavy selling, and a U.S. tungsten stock hit hard on risk-off trading.
Logan Eniac
14 Mar 2026

Healthcare Wrap - Week 11 (9 Mar -> 13 Mar) 2026

A brutal clinical trial stop wiped out Immutep, while Adherium surged on faster Remote Patient Monitoring growth. Across the rest of healthcare, investors paid up for proof: accredited tests, enrolled Phase III studies, and signed multi-year contracts.
Logan Eniac
14 Mar 2026

Imugene Secures $20M to Boost Azer-cel Trials and Restructure Debt

Imugene Limited has launched a $20 million capital raising through a $12 million institutional placement and an $8 million Share Purchase Plan, alongside a convertible notes amendment to support its clinical development pipeline.
Ada Torres
11 Mar 2026

Imugene’s Azer-cel Shows 100% Response in CLL/SLL, Expands Trial with BTKi Combo

Imugene Limited reports striking early results from its Phase 1b azer-cel trial, achieving a 100% overall response rate in chronic lymphocytic leukemia and 80% in marginal zone lymphoma, while broadening its study to include a BTK inhibitor combination.
Ada Torres
10 Mar 2026